Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06670521 · ClinicalTrials.gov registry record · Phase 2

Corticosteroids for Post-Extubation Dysphagia

A Phase 2 study of Dysphagia and Laryngeal Edema, sponsored by University of Colorado, Denver.

Recruiting
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT06670521: Recruiting Phase 2 study of Dysphagia and Laryngeal Edema, sponsored by University of Colorado, Denver.

NCT06670521 is a Phase 2 study of Dysphagia and Laryngeal Edema that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 80 participants, below the 170-participant average among 35 other Dysphagia trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06670521, a Phase 2 study of Dysphagia and Laryngeal Edema, is actively recruiting participants, sponsored by University of Colorado, Denver.

RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This is a placebo-controlled, double-blind randomized trial of a short course of intravenous corticosteroids for Acute Respiratory Failure Survivors with Fiberoptic Endoscopic Evaluation of Swallowing (FEES) documented laryngeal edema. Study was leveraged using the existing R01 grant infrastructure COMIRB # 21-3873, study design, and research methods. Patients for the study proposed will have already been enrolled in the R01 longitudinal cohort study. The sites to perform this study include Colorado, BU, Yale, and Stanford. Those R01-enrolled patients with laryngeal edema on their initial FEES examination: defined as the revised Patterson edema score greater than zero, will be approached for enrollment.

Primary Outcome

Investigators hypothesize that corticosteroids will be more effective (a larger pre/post reduction in the revised Patterson Edema scale) for resolution of swallowing dysfunction in patients recovering from acute respiratory failure with the presence of laryngeal edema on a FEES examination. Change is defined as the pre-study total FEES revised Patterson Edema scale minus the post-study total FEES revised Patterson Edema scale. Improvement in the total revised Patterson Edema scale would a positi

Interventions

  • DRUG Methylprednisolone
  • DRUG Normal Saline

Study Locations (1)

Colorado

  • University of Colorado - Aurora

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-11-13
Est. Completion 2027-05-31
Phase Phase 2
University of Colorado, Denver

1,283 total trials

What NCT06670521 shows while recruiting

NCT06670521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 170-participant average among 35 other Dysphagia trials with a reported enrollment target (53% lower).

The record links to 2 conditions, with Dysphagia appearing as the primary indexed condition, and to 2 interventions - of which Methylprednisolone is the first listed.

NCT06670521 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT06670521 about?

NCT06670521 is a clinical study titled "Corticosteroids for Post-Extubation Dysphagia". This is a placebo-controlled, double-blind randomized trial of a short course of intravenous corticosteroids for Acute Respiratory Failure Survivors with Fiberoptic Endoscopic Evaluation of Swallowing (FEES) documented laryngeal edema. Study was leveraged using the existing R01 grant infrastructure ...

What is the current status of trial NCT06670521?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-11-13. Estimated completion is 2027-05-31.

What conditions does trial NCT06670521 study?

This clinical trial studies the following conditions: Dysphagia, Laryngeal Edema.

What interventions are being tested in trial NCT06670521?

The interventions under investigation include: Methylprednisolone (DRUG), Normal Saline (DRUG).

Who is sponsoring clinical trial NCT06670521?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06670521 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dysphagia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06670521's enrollment target sits among peer trials

80 18th of 35 higher than 18 of 35 other Dysphagia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dysphagia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06670521, the US trial registry maintained by the National Library of Medicine. NCT06670521 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.